Not long ago, at the "Progress and Hot Spots of Cancer Bone Metastasis Research" seminar held in Beijing, Peter Duschi, head of the Austrian Breast and Colorectal Cancer Research Group, shared a groundbreaking study conducted by European Zui in collaboration with Novartis AG. The research focused on Zhaitai, a novel treatment that showed remarkable anti-tumor effects in early breast cancer patients, particularly those who were premenopausal and had hormone receptor-positive tumors. The findings revealed that when Zhaitai was added to standard endocrine therapy after surgery, it reduced the risk of primary tumor recurrence by 36% compared to endocrine therapy alone.
Bone metastasis is a common complication in advanced cancers, affecting approximately 20-30% of patients whose cancer spreads to bone tissue. This is especially prevalent in patients with lung, breast, and prostate cancer. In addition to traditional treatments like chemotherapy, radiotherapy, and isotope therapy, bisphosphonates have become the preferred treatment for managing bone metastases globally. Among them, Zhaitai stands out as the only bisphosphonate approved worldwide for treating various types of tumor-related bone metastases.
In breast cancer cases, estrogen plays a key role in tumor recurrence. Endocrine therapy helps lower estrogen levels, but it can also lead to accelerated bone loss, especially in premenopausal and postmenopausal women. To address this, a large-scale study involving 1,803 premenopausal women with estrogen and progesterone receptor-positive breast cancer was conducted. Researchers combined endocrine therapy with Zhaitai to evaluate its impact on disease-free survival and tumor recurrence. The results showed that patients receiving Zhaitai experienced lower rates of local recurrence, distant metastasis, and contralateral breast cancer, confirming its strong anti-tumor activity.
Experts from leading institutions, including Professor Xu Binghe from the Chinese Academy of Medical Sciences and Professor Zhang Li from Sun Yat-sen University, praised the study as a major breakthrough in oncology this year. They emphasized that future research will expand to other cancers, such as lung and prostate cancer, where similar anti-tumor strategies are being explored.
Currently, extensive clinical trials have demonstrated that Zhaitai is highly effective in managing bone metastases in breast, lung, and prostate cancers, as well as in multiple myeloma. As a result, the U.S. FDA has approved Zhaitai as the only bisphosphonate proven effective for bone metastases across various solid tumors and multiple myeloma. It is also recognized for its safety profile and ease of administration, making it a valuable option for patients worldwide.
Portable Water Fire Extinguisher
Portable Water Fire Extinguisher,Water Foam Fire Extinguisher,Water Fire Extinguisher,Water-Based Fire Extinguisher
Nanjing Txfire International Trade Co., Ltd , https://www.txfireequipment.com